Roger Cady
YOU?
Author Swipe
View article: Migraine-Related Burden, Treatment Interventions, and Healthcare Experiences by Race and Ethnicity: Results of the Migraine Report Card Survey
Migraine-Related Burden, Treatment Interventions, and Healthcare Experiences by Race and Ethnicity: Results of the Migraine Report Card Survey Open
Migraine studies consistently have low enrollment of non-White and/or Hispanic participants. This exploratory analysis assesses burden, treatment interventions, and care in people with high-frequency migraine and medication overuse (HFM + …
View article: Headache-related stigma and quality of life in adults with frequent headaches/migraine and frequent medication use: a plain language summary
Headache-related stigma and quality of life in adults with frequent headaches/migraine and frequent medication use: a plain language summary Open
What is this summary about? This summary reports data collected from the Migraine Report Card study.The Harris Poll Migraine Report Card study was a survey for people living with migraine. This survey asked about their experiences with hea…
View article: A population-based survey of Americans with frequent migraine and acute medication use: A plain language summary
A population-based survey of Americans with frequent migraine and acute medication use: A plain language summary Open
The findings from this survey showed many ways that headaches/migraine care can improve, including talking about mental and emotional well-being, making sure the treatment plan works and does not have side effects that cannot be tolerated,…
View article: Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache
Long‐term effectiveness of eptinezumab in the treatment of patients with chronic migraine and medication‐overuse headache Open
Objective This post hoc analysis of the PREVAIL study explored the effectiveness of eptinezumab for up to 2 years of open‐label treatment in the subgroup of patients with chronic migraine who had a confirmed diagnosis of medication‐overuse…
View article: Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine
Improving to Four or Fewer Monthly Headache Days Per Month Provides a Clinically Meaningful Therapeutic Target for Patients with Chronic Migraine Open
ClinicalTrials.gov (Identifier: NCT02974153) ( https://clinicaltrials.gov/ct2/show/NCT02974153 ).
View article: P.015 Preventive treatment with eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2
P.015 Preventive treatment with eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2 Open
Background: This post hoc analysis of the PROMISE-2 data provides an assessment of the total preventive migraine efficacy of eptinezumab over 24 weeks in patients with a dual diagnosis of chronic migraine (CM) and medication overuse headac…
View article: Treatment with Eptinezumab for Migraine Prevention in People with Chronic Migraine and Medication-Overuse Headache: A Plain Language Summary
Treatment with Eptinezumab for Migraine Prevention in People with Chronic Migraine and Medication-Overuse Headache: A Plain Language Summary Open
Eptinezumab is beneficial for people who often use acute medication(s) due to frequent headache episodes or migraine attacks.
View article: Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment
Patient preferences for attributes of injected or infused preventive migraine medications: Findings from a discrete choice experiment Open
Objective To assess preferences among adults with migraine for differentiating attributes of injected or infused preventive treatment options and evaluate their importance in determining a treatment choice. Background Adults with migraine …
View article: Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized <scp>PROMISE</scp> ‐2 trial
Eptinezumab improved patient‐reported outcomes in patients with migraine and medication‐overuse headache: Subgroup analysis of the randomized <span>PROMISE</span> ‐2 trial Open
Objective To evaluate the effect of eptinezumab on patient‐reported outcomes in patients with chronic migraine (CM) and medication‐overuse headache (MOH). Background MOH is a secondary headache disorder commonly occurring in patients with …
View article: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial Open
Background Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and …
View article: P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine
P.016 Reduction in migraine-associated burden over 24 weeks of treatment with eptinezumab in patients with chronic migraine Open
Background: To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine (CM) following eptinezumab treatment. Methods: PROMISE-2 (NCT02974153) was a double-blind, placebo-controlled, …
View article: Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials Open
Objective To develop a multivariable model assessing factors predicting a second‐dose response to eptinezumab treatment over weeks 13–24 in patients with migraine initially reporting a suboptimal response over weeks 1–12. Background Eptine…
View article: Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention
Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention Open
Objective To assess the utility of the novel patient‐identified (PI) most bothersome symptom (MBS) measure from PROMISE‐2, a phase 3 trial of eptinezumab for the preventive treatment of chronic migraine. Background Relief of bothersome mig…
View article: Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine Open
Objective To examine changes in the occurrence, severity, and symptoms of headache episodes in patients with chronic migraine following eptinezumab treatment. Methods PROMISE-2 was a double-blind, placebo-controlled, parallel-group trial t…
View article: Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2 Open
Background This post hoc subgroup analysis evaluated the efficacy and safety of eptinezumab for migraine prevention in patients with migraine and self-reported aura. Methods PROMISE-1 (NCT02559895; episodic migraine) and PROMISE-2 (NCT0297…
View article: Eptinezumab for migraine prevention in patients 50 years or older
Eptinezumab for migraine prevention in patients 50 years or older Open
Treatment with eptinezumab was efficacious, tolerable, and safe in patients ≥50 years with EM or CM, congruent with results from the overall study population.
View article: Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study Open
Background Demonstrating therapeutic value from the patient perspective is important in patient-centered migraine management. The objective of this study was to investigate the impact of eptinezumab, a preventive migraine treatment, on pat…
View article: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials Open
Background PROMISE-1 and PROMISE-2 evaluated the preventive efficacy, tolerability, and safety of eptinezumab, a calcitonin gene-related peptide–targeted monoclonal antibody, in adults with episodic (EM) and chronic migraine (CM), finding …